Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
    Meeting Abstract

    Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
    Meeting Abstract

    Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S. J.; Fayette, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Long-term outcomes with nivolumab vesrsus docetaxel in patients with advanced NSCLC: CheckMate 017 and CheckMate 057 2-year update
    Meeting Abstract

    Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S.; Fayette, J.; more...
    Asia-Pacific Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer
    Journal Article

    Rizvi, N. A.; Hellmann, M. D.; Brahmer, J. R.; Juergens, R. A.; Borghaei, H.; Gettinger, S.; Chow, L. Q.; Gerber, D. E.; Laurie, S. A.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer
    Journal Article

    Gettinger, S.; Rizvi, N. A.; Chow, L. Q.; Borghaei, H.; Brahmer, J.; Ready, N.; Gerber, D. E.; Shepherd, F. A.; Antonia, S.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
    Journal Article

    Ribas, A.; Hamid, O.; Daud, A.; Hodi, F. S.; Wolchok, J. D.; Kefford, R.; Joshua, A. M.; Patnaik, A.; Hwu, W. J.; Weber, J. S.; more...
    JAMA - Journal of the American Medical Association (2016)

    Fulltext@MSK | Save
  • Phase 3, randomized trial (CheckMate 017) of nivolumab (NIVO) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Reckamp, K.; Brahmer, J. R.; Spigel, D. R.; Rizvi, N. A.; Poddubskaya, E.; West, H.; Eberhardt, W. E. E.; Baas, P.; Antonia, S. J.; Pluzanski, A.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced, refractory squamous non-small cell lung cancer
    Meeting Abstract

    Horn, L.; Rizvi, N. A.; Mazières, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Léna, H.; Minenza, E.; Mennecier, B.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Rizvi, N. A.; Gettinger, S. N.; Goldman, J. W.; Hellmann, M. D.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J. R.; Shen, Y.; Harbison, C.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save